

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Amoxi 25 mg/mL Oral Suspension (DIN 00628131) manufactured by Apotex Inc., Jamp-Amoxicillin 50 mg/mL Oral Suspension (DIN 02535815) manufactured by Jamp Pharma Corporation will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **May 26, 2023**.

As of **May 26, 2023**, all claims for **Jamp-Amoxicillin 50 mg/mL Oral Suspension (DIN 02535815)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

Due to the unavailability of Folic Acid 5 mg Tablet (DIN 00426849) manufactured by AA Pharma Inc., Jamp-Folic 5 mg Tablet (DIN 02366061) manufactured by Jamp Pharma Corporation and Sandoz Folic Acid 5 mg Tablet (DIN 02285673) manufactured by Sandoz Canada Inc., Jamp-Folic Acid 1 mg Tablet (DIN 80053274) manufactured by Jamp Pharma Corporation will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **June 12, 2023**.

As of **June 12, 2023**, all claims for **Jamp-Folic Acid 1 mg Tablet (DIN 80053274)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

Removal of Temporary Benefits from the *ADBL*

Due to the shortage of Isopto Carpine 2% Ophthalmic Solution (DIN 00000868) manufactured by Novartis Pharmaceuticals Canada Inc., Pilocarpine Nitrate 2% Ophthalmic Solution (DIN 02148463) manufactured by Bausch and Lomb Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for Isopto Carpine 2% Ophthalmic Solution (DIN 00000868) has been resolved.

Pilocarpine Nitrate 2% Ophthalmic Solution (DIN 02148463) will no longer be considered a temporary benefit for the *ADBL* after **July 17, 2023**. The above grouping was removed from the Critical Supply Product List **June 15, 2023**.

Due to the shortage of Humatrope 6 mg Injection (DIN 02243077) and Humatrope 12 mg Injection (DIN 02243078) manufactured by Eli Lilly Canada Inc., Humatrope 24 mg Injection (DIN 02243079) manufactured by Eli Lilly Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

continued next page

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Humatrope 6 mg Injection (DIN 02243077) and Humatrope 12 mg Injection (DIN 02243078) has been resolved.

Humatrope 24 mg Injection (DIN 02243079) will no longer be considered a temporary benefit for the *ADBL* after **July 17, 2023**. The above grouping was removed from the Critical Supply Product List **June 15, 2023**.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Teva-Sucralfate 1 g Tablet (DIN 02045702) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 16, 2023**. The following grouping was removed from the Critical Supply Product List **June 16, 2023**.

SUCRALFATE

1 G TABLET

00002125250	APO-SUCRALFATE	APX	\$ 0.3089
00002045702	TEVA-SUCRALFATE	TEV	\$ 0.3089
00002100622	SULCRATE	AXC	\$ 0.6695

Alberta Blue Cross has confirmed that the shortage for Apo-Dabigatran 110 mg Capsule (DIN 02468905) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 19, 2023**. The following grouping was removed from the Critical Supply Product List **June 19, 2023**.

DABIGATRAN ETEXILATE

110 MG CAPSULE

00002468905	APO-DABIGATRAN	APX	\$ 1.2540
00002312441	PRADAXA	BOE	\$ 1.7309

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
 403-294-4041 (Calgary and area)
 1-800-361-9632 (toll free)
 FAX 780-498-8406 (Edmonton and area)
 FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

